A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2016
At a glance
- Drugs Parsatuzumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms CONGO
- Sponsors Genentech
- 24 Aug 2016 Status changed from discontinued to completed.
- 12 Jul 2016 Status changed from completed to discontinued.
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.